Bortezomib-D8 (Major)
|
|
Bortezomib-D8 (Major) Eigenschaften
- Schmelzpunkt:
- 115-117°C
- storage temp.
- Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Sicherheit
Bortezomib-D8 (Major) Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Off-White SolidVerwenden
Labeled Bortezomib, whcih the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all euBortezomib-D8 (Major) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Bortezomib-D8 (Major) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 5)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate | |
---|---|---|---|---|---|
Chemsky(shanghai)International Co.,Ltd. | 021-50135380 |
shchemsky@sina.com | China | 32321 | 50 |
Cato Research Chemicals Inc. | 020-81960175 |
min.he@cato-chem.com | China | 1955 | 55 |
- Bortezomib-D8 (Major)
- Velcade-D8, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic Acid-D8
- C19H17D8BN4O4
- Inhibitors
- Boron Derivatives
- Intermediates & Fine Chemicals
- Isotope Labeled Compounds
- Pharmaceuticals
- Isotope Labelled Compounds